Gilead Sciences

Health Care Biotechnology Foster City, California Last filing Feb 24, 2026 · FY2025

                    Revenue
                    FY2025
                
$29.4B
                    3y CAGR +2.6%
                    
                    P34
                    
                    +2.4%
                    
                    Net income
                    FY2025
                
$8.5B
                    Net margin +28.9%
                    
                    P95
                    
                    +1672.9%
                    
                    Total assets
                    FY2025
                
$59.0B
                    ROA +14.4%
                    
                    P88
                    
                    +0.0%
                    
                    Operating cash flow
                    FY2025
                
$10.0B
                    FCF margin +32.1%
                    
                    P98
                    
                    -7.5%

19 yrs · FY2007–FY2025 9 filed · 0 derived · 0 blank

1Y 3Y 5Y 10Y

Dollars % of revenue % of assets YoY % CAGR

Each cell as a share of that year’s revenue.

Balance Sheet

Assets, liabilities, and equity

29 accounts · 10 years

Total assets $59.0B

Total liabilities $11.8B

Shareholders equity $22.7B

Account	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Assets
Cash and Cash Equivalents	25.7%	34.7%	22.4%	19.8%	19.5%	24.3%	51.8%	81.1%	29.1%	27.1%
Short Term Investments	0.0%	5.5%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Accounts Receivable	16.7%	15.4%	17.2%	17.5%	16.5%	19.8%	16.0%	15.0%	14.8%	14.9%
Inventory	6.0%	5.9%	6.6%	5.5%	5.9%	6.8%	4.1%	3.7%	3.1%	5.2%
Prepaid Expenses	13.7%	10.6%	8.8%	6.5%	7.8%	8.2%	6.4%	7.3%	6.4%	5.2%
Total Current Assets	62.3%	66.7%	59.3%	52.9%	54.1%	64.8%	135.0%	162.0%	121.9%	67.3%
Property,Plant and Equipment	19.0%	18.8%	19.6%	20.1%	18.8%	20.1%	20.1%	18.1%	12.6%	9.4%
Goodwill	28.2%	28.9%	30.7%	30.5%	30.5%	32.8%	18.3%	18.6%	15.9%	3.9%
Intangible Assets	57.7%	69.4%	97.6%	105.9%	122.5%	134.2%	61.4%	71.1%	65.5%	29.5%
Deferred Tax Assets	6.7%	20.8%	20.5%	17.2%	15.0%	16.0%	14.0%	5.5%	4.4%	4.6%
Other Noncurrent Assets	16.5%	21.4%	17.7%	17.6%	18.2%	23.1%	33.1%	11.5%	10.4%	7.3%
Total Assets	200.5%	205.2%	229.1%	231.6%	248.9%	277.1%	274.5%	287.8%	269.2%	187.5%
Liabilities
Accounts Payable	2.4%	2.9%	2.0%	3.3%	2.6%	3.4%	3.2%	3.6%	3.1%	4.0%
Accrued Liabilities	0.0%	7.9%	8.6%	8.0%	22.5%	17.6%	13.7%	14.2%	12.9%	9.2%
Current Portion of Long Term Debt	9.5%	6.3%	6.6%	8.3%	5.6%	11.2%	11.1%	12.4%	10.5%	0.0%
Other Current Liabilities	13.4%	19.0%	18.9%	16.8%	—	—	—	—	—	—
Total Current Liabilities	40.1%	41.7%	41.6%	41.2%	42.5%	46.2%	43.5%	47.9%	44.6%	30.3%
Long Term Debt	75.2%	86.6%	85.5%	84.2%	92.2%	116.0%	98.4%	111.1%	118.0%	86.7%
Deferred Tax Liabilities	1.4%	2.5%	5.9%	9.8%	16.0%	26.6%	7.0%	7.9%	5.3%	0.4%
Other Noncurrent Liabilities	4.0%	4.5%	4.7%	4.3%	3.6%	20.8%	4.5%	4.7%	2.1%	1.0%
Total Liabilities	40.1%	41.7%	41.6%	41.2%	42.5%	46.2%	43.5%	47.9%	44.6%	30.3%
Equity
Preferred Stock	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Common Stock	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Additional Paid In Capital	30.3%	26.8%	24.0%	20.3%	17.1%	15.7%	13.6%	10.3%	4.8%	1.5%
Retained Earnings	46.6%	40.0%	60.1%	57.5%	59.8%	58.2%	86.4%	86.0%	72.8%	59.7%
Accumulated Other Comprehensive Income	0.1%	0.5%	0.1%	0.0%	0.3%	-0.2%	0.4%	0.4%	0.6%	0.9%
Noncontrolling Interest	-0.3%	-0.3%	-0.3%	-0.1%	-0.0%	0.1%	0.6%	0.7%	0.2%	1.6%
Total Stockholders Equity	77.1%	67.2%	84.2%	77.9%	77.2%	73.7%	100.3%	96.7%	78.3%	62.1%
Total Liabilitiesand Equity	200.5%	205.2%	229.1%	231.6%	248.9%	277.1%	274.5%	287.8%	269.2%	187.5%

Income Statement

Revenue, expense, and profitability

20 accounts · 10 years

Revenue $29.4B

Operating income $10.0B

Net income $8.5B

Account	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
IncomeStatement
Revenues Total Revenue	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Expenses Cost of Revenue	21.2%	21.7%	24.0%	20.7%	24.2%	18.5%	20.8%	21.9%	16.7%	14.0%
Expenses Research and Development	19.7%	20.5%	21.1%	18.2%	16.9%	20.0%	40.6%	22.7%	14.3%	16.8%
Expenses Selling,General and Administrative	19.6%	21.2%	22.5%	20.8%	19.2%	20.9%	19.5%	18.3%	14.9%	11.2%
Expenses Depreciation and Amortization	8.2%	8.3%	8.5%	6.6%	6.2%	4.9%	—	—	—	—
Expenses Share Based Compensation	3.0%	2.9%	2.8%	2.3%	2.3%	2.6%	2.8%	3.8%	2.4%	1.3%
Expenses Restructuring and Asset Impairment	0.5%	0.7%	1.9%	—	—	—	—	—	—	—
Expenses Operating Expenses	66.0%	94.2%	72.0%	73.1%	63.7%	83.5%	80.9%	62.9%	45.9%	42.0%
Other Income Expense Operating Income	34.0%	5.8%	28.0%	26.9%	36.3%	16.5%	19.1%	37.1%	54.1%	58.0%
Other Income Expense Interest Income	1.2%	1.0%	1.4%	0.4%	—	—	—	—	—	—
Other Income Expense Interest Expense	3.5%	3.4%	3.5%	3.4%	3.7%	4.0%	4.4%	4.9%	4.3%	3.2%
Other Income Expense Other Income/expense	-0.0%	-0.0%	-0.0%	-0.1%	—	—	—	—	—	—
Other Income Expense Income Before Tax	33.3%	2.4%	25.3%	21.3%	30.3%	6.8%	23.0%	35.2%	51.8%	56.3%
Income Tax Income Tax Expense	4.4%	0.7%	4.6%	4.6%	7.6%	6.4%	-0.9%	10.6%	34.0%	11.9%
net Income net Income	28.9%	1.7%	20.9%	16.8%	22.8%	0.5%	24.0%	24.7%	17.7%	44.4%
net Income Comprehensive Income	28.6%	2.0%	21.0%	16.5%	23.3%	-0.1%	24.0%	25.6%	17.3%	45.1%
Earnings Per Share Basic Eps	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Earnings Per Share Diluted Eps	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Earnings Per Share Weighted Average Shares Basic	4.2%	4.3%	4.6%	4.6%	4.6%	5.1%	5.7%	5.9%	5.0%	4.4%
Earnings Per Share Weighted Average Shares Diluted	4.3%	4.4%	4.6%	4.6%	4.6%	5.1%	5.7%	5.9%	5.1%	4.5%

Cash Flow Statement

Operating, investing, and financing flows

23 accounts · 10 years

Operating cash flow $10.0B

Investing cash flow $-4.8B

Financing cash flow $-7.7B

Account	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
CashFlow
Operating Activities net Income	28.9%	1.7%	20.9%	16.8%	22.8%	0.5%	24.0%	24.7%	17.7%	44.4%
Operating Activities Depreciation and Amortization	1.3%	1.3%	1.3%	1.2%	1.2%	1.2%	1.1%	1.0%	0.9%	0.6%
Operating Activities Stock Based Compensation	3.0%	2.9%	2.8%	2.3%	2.3%	2.6%	2.8%	3.8%	2.4%	1.3%
Operating Activities Deferred Income Taxes	0.5%	-6.4%	-3.5%	-5.7%	-0.4%	-0.9%	9.3%	-1.3%	0.3%	0.4%
Operating Activities Changes In Operating Assets and Liabilities	5.4%	3.3%	2.8%	1.1%	1.1%	9.3%	0.8%	-7.3%	-8.1%	-0.4%
Operating Activities net Cash From Operating Activities	34.0%	37.7%	29.5%	33.3%	41.7%	33.1%	40.7%	38.0%	45.6%	56.1%
Investing Activities Capital Expenditures	1.9%	1.8%	2.2%	2.7%	2.1%	2.6%	3.7%	4.2%	—	—
Investing Activities Business Acquisitions	3.6%	16.8%	4.2%	6.6%	5.8%	105.0%	18.9%	0.0%	39.9%	0.0%
Investing Activities Purchases of Investments	13.4%	0.8%	7.1%	6.5%	12.9%	82.3%	135.7%	46.2%	89.3%	84.3%
Investing Activities Proceeds From Sale of Investments	0.2%	1.1%	4.9%	5.8%	8.0%	94.1%	33.5%	6.9%	40.0%	42.9%
Investing Activities Other Investing Activities	-0.0%	-0.2%	0.0%	0.0%	-0.1%	-0.0%	1.9%	0.9%	0.0%	—
Investing Activities net Cash From Investing Activities	-16.3%	-12.0%	-8.4%	-9.0%	-11.5%	-59.2%	-34.8%	64.9%	-61.6%	-39.4%
Financing Activities Proceeds From Debt	0.0%	12.0%	7.3%	0.0%	0.0%	33.1%	0.0%	0.0%	34.4%	17.4%
Financing Activities Repayment of Debt	6.1%	6.9%	8.3%	5.5%	17.4%	10.1%	12.2%	28.2%	6.9%	6.5%
Financing Activities Repurchase of Common Stock	6.5%	4.0%	3.7%	5.1%	2.0%	6.4%	7.8%	13.1%	3.7%	36.2%
Financing Activities Dividends Paid	13.6%	13.6%	14.0%	13.6%	13.2%	14.0%	14.4%	13.4%	10.5%	8.1%
Financing Activities Proceeds From Stock Issuance	1.4%	1.5%	0.9%	1.1%	0.6%	1.0%	0.9%	1.3%	0.9%	0.7%
Financing Activities Other Financing Activities	-1.5%	-1.0%	-1.0%	-0.6%	-0.5%	-0.6%	-0.5%	-2.2%	-1.3%	-0.9%
Financing Activities net Cash From Financing Activities	-26.3%	-11.9%	-18.9%	-23.7%	-32.5%	3.1%	-34.0%	-55.7%	13.0%	-32.0%
Cash Reconciliation Effect of Exchange Rate On Cash	0.3%	-0.1%	0.2%	-0.2%	-0.1%	0.2%	-0.0%	-0.4%	0.5%	0.1%
Cash Reconciliation net Change In Cash	-8.2%	13.6%	2.5%	0.3%	-2.4%	-22.8%	-28.1%	46.8%	-2.5%	-15.2%
Cash Reconciliation Cash At Beginning of Period	25.7%	34.7%	22.4%	19.8%	19.5%	24.3%	51.8%	81.1%	29.1%	27.1%
Cash Reconciliation Cash At End of Period	25.7%	34.7%	22.4%	19.8%	19.5%	24.3%	51.8%	81.1%	29.1%	27.1%

Key Ratios

Margins, returns, liquidity, leverage, efficiency

Computed at import · 10 years

Ratio	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Profitability
Gross margin	+78.8%	+78.3%	+76.0%	+79.3%	+75.8%	+81.5%	+79.2%	+78.1%	+83.3%	+86.0%
Operating margin	+34.0%	+5.8%	+28.0%	+26.9%	+36.3%	+16.5%	+19.1%	+37.1%	+54.1%	+58.0%
Net margin	+28.9%	+1.7%	+20.9%	+16.8%	+22.8%	+0.5%	+24.0%	+24.7%	+17.7%	+44.4%
FCF margin	+32.1%	+35.8%	+27.4%	+30.6%	+39.6%	+30.5%	+37.1%	+33.8%	—	—
Growth
Revenue CAGR (3y)	+2.6%	+1.7%	+3.2%	+6.7%	+7.3%	-1.8%	-9.6%	-12.2%	+1.6%	+39.5%
Returns
ROE	+37.5%	+2.5%	+24.8%	+21.6%	+29.5%	+0.7%	+23.9%	+25.5%	+22.6%	+71.5%
ROA	+14.4%	+0.8%	+9.1%	+7.3%	+9.2%	+0.2%	+8.7%	+8.6%	+6.6%	+23.7%
ROIC	+21.7%	+3.2%	+14.9%	+14.0%	+17.5%	+0.5%	+12.1%	+18.7%	+10.4%	+37.6%
Liquidity
Current ratio	1.55x	1.60x	1.43x	1.29x	1.27x	1.40x	3.10x	3.38x	2.74x	2.22x
Quick ratio	1.06x	1.20x	0.95x	0.91x	0.85x	0.96x	1.56x	2.01x	0.98x	1.38x
Leverage
D/E	0.52x	0.62x	0.49x	0.53x	0.55x	0.63x	0.43x	0.50x	0.57x	0.49x
Interest coverage	9.79x	1.70x	8.06x	7.84x	9.91x	4.14x	4.31x	7.61x	12.63x	18.29x
Efficiency
Asset turnover	0.50x	0.49x	0.44x	0.43x	0.40x	0.36x	0.36x	0.35x	0.37x	0.53x
Cash conversion cycle	+123d	+107d	+132d	+103d	+111d	+139d	+75d	+57d	+53d	+87d

Valuation

Price against fundamentals

FY2025 fundamentals · no price

No price data cached, so there is nothing to multiply. Load prices from the Stock Data tab and this panel reprices itself.

Notes

Your annotations

Not watched

Gilead Sciences

Assets, liabilities, and equity

Revenue, expense, and profitability

Operating, investing, and financing flows

Margins, returns, liquidity, leverage, efficiency

Price against fundamentals

Your annotations

One-year price and volume history

Price data unavailable

Assets, liabilities, and equity

Revenue, expense, and profitability

Operating, investing, and financing flows

Margins, returns, liquidity, leverage, efficiency

Price against fundamentals

Your annotations

One-year price and volume history

Price data unavailable

Recent price history